22,000 employees

in 149 countries, including 5,000 in France.

5 major R&D areas

cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes.

100 Million patients

treated daily with Servier medicinal products and generics.

15 international centers of clinical development

and 3 research centers.

16 chemical & pharmaceutical production sites

producing chemicals and pharmaceuticals worldwide.

4,2 billion euros turnover

comprising 2.9 billion euros for Servier and 1.2 billion euros for generics.

25 % of turnover from Servier drugs is invested in R&D

excluding generics.

No. 2 pharmaceutical company in france

no. 30 in the world; 3 research centres including 2 in France.

No.1 in cardiology in France

no. 2 in Europe, No. 8 in the world.

2nd leading preferred partner for research centers conducting clinical trials

According to CenterWatch rankings from March 2017, based on a total of 23 pharmaceutical companies

Servier earned the highest score of A3++

As in previous years, this high score represents excellence in honoring financial commitments.

Participation reached 36.6% of the trade balance surplus in france

In pharmaceuticals and fine chemicals, amounting to 1.4 billion euros.